Mechanism Comparison
Ghrelin Receptor Agonism vs Lipolytic GH Fragment Activity
Side-by-side comparison of how ghrelin receptor agonism and lipolytic gh fragment activity differ in receptor target, downstream effects, evidence base, and the peptides that use each mechanism.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Activation of the growth hormone secretagogue receptor (GHSR-1a) — the ghrelin receptor — to drive GH release through a second pathway.
Compounds using this mechanism
Growth hormone C-terminal fragment that selectively promotes lipolysis without the anabolic effects of full-length GH.
Compounds using this mechanism
Side-by-side mechanism table
| Attribute | Ghrelin Agonism | GH Fragment (Lipolytic) |
|---|---|---|
| Pathway family | Ghrelin / GHSR-1a signaling | GH C-terminal fragment / lipolysis |
| Therapeutic areas | GH deficiency research, Age-related body composition decline, Cachexia research | Obesity research, Osteoarthritis (research), Fat loss |
| Compounds | 2 | 1 |
| Total studies | 108 | 23 |
| Human studies | 29 | 2 |
| FDA approved | 0 | 0 |
| In clinical trials | 0 | 0 |
| Research-only | 1 | 1 |
| Avg evidence level | L3.5 | L2 |
| Primary downstream effects |
|
|
How each mechanism works
Ghrelin Receptor Agonism
- 1Binds to the ghrelin receptor (GHSR-1a), a class A GPCR.
- 2Activates Gαq → phospholipase C → IP3 / DAG → Ca²⁺ release.
- 3Amplifies GH release from pituitary somatotrophs.
- 4Synergizes with GHRH signaling when co-administered.
- 5Stimulates orexigenic neurons in the arcuate nucleus.
Lipolytic GH Fragment Activity
- 1Mimics the lipolytic domain of full-length GH.
- 2Activates hormone-sensitive lipase in adipocytes.
- 3Promotes release of free fatty acids from fat stores.
- 4Does not activate IGF-1 or induce insulin resistance.
- 5May support cartilage repair (preclinical).
Evidence notes
Ghrelin Agonism
MK-677 (ibutamoren) is oral and has Phase II data. Ipamorelin is a selective peptide ghrelin agonist with preclinical + pilot human data.
GH Fragment (Lipolytic)
Phase II human trials exist; not FDA approved. Safety profile is favorable in trials.
When each mechanism is most relevant
Ghrelin Receptor Agonism
- Average evidence L3.5 across compounds using this mechanism
- No FDA-approved compounds yet — research use only
- 1 compound restricted from compounding (FDA Category 2)
- Mechanism-driven limitations: Increased appetite can drive weight gain
Lipolytic GH Fragment Activity
- No FDA-approved compounds yet — research use only
- Mechanism-driven limitations: Phase 2 weight-loss data largely negative
Frequently asked
What is the difference between Ghrelin Receptor Agonism and Lipolytic GH Fragment Activity?
Ghrelin Receptor Agonism: Activation of the growth hormone secretagogue receptor (GHSR-1a) — the ghrelin receptor — to drive GH release through a second pathway. Lipolytic GH Fragment Activity: Growth hormone C-terminal fragment that selectively promotes lipolysis without the anabolic effects of full-length GH. The pathways differ in receptor target (Ghrelin / GHSR-1a signaling vs GH C-terminal fragment / lipolysis) and produce different downstream effects, even when the therapeutic end-goals overlap.
Which mechanism has more FDA-approved compounds?
Ghrelin Receptor Agonism currently has 0 FDA-approved compound(s) out of 2 that use this mechanism. Lipolytic GH Fragment Activity has 0 FDA-approved compound(s) out of 1. FDA approval reflects demonstrated efficacy and safety for a specific indication, not the intrinsic quality of the mechanism itself.
What therapeutic areas does each mechanism address?
Ghrelin Receptor Agonism is primarily researched for gh deficiency research, age-related body composition decline, cachexia research. Lipolytic GH Fragment Activity is primarily researched for obesity research, osteoarthritis (research), fat loss. The two address largely distinct therapeutic areas, but are sometimes compared because of adjacent patient populations.
Can compounds targeting Ghrelin Agonism and GH Fragment (Lipolytic) be combined?
Combination protocols exist in clinical literature and some practice settings, but evidence for combined safety is generally weaker than evidence for either mechanism alone. Different mechanisms can produce complementary effects, but also additive or unpredictable adverse events. Any stacking should involve a qualified clinician familiar with both pathways.
Which mechanism has deeper clinical evidence?
Compounds acting through Ghrelin Receptor Agonism account for 108 indexed studies (29 human). Compounds acting through Lipolytic GH Fragment Activity account for 23 indexed studies (2 human). Study depth is only one component of evidence quality — trial design, replication, and endpoint clinical relevance matter more than raw counts.
Related mechanism comparisons
Mechanism hub
Ghrelin Receptor Agonism →
Mechanism hub
Lipolytic GH Fragment Activity →